Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

SLXP 156.50 -0.38 (-0.24%)
price chart
Salix Pharmaceuticals, Ltd. (SLXP) Q4 Revenue Hits A Record Low
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) on Monday announced its fourth-quarter financial results for fiscal'14 (4QFY14), registering a hefty decline in revenue as it ceases sales to wholesalers.
What to Expect When Salix Pharmaceuticals (SLXP) Reports Fourth Quarter ...  TheStreet.com
Research Analysts' Weekly Ratings Changes for Salix Pharmaceuticals (SLXP)  Dakota Financial News
Salix Pharmaceuticals, Ltd. (SLXP) Q4 Earnings Preview: Declining Sales Of ...
Salix Pharmaceuticals, Ltd. is scheduled to announce fourth-quarter financial results for fiscal'14 (4QFY14) on March 4 after markets close.
3 Pharma Companies Competing To Acquire Salix Pharmaceuticals, Ltd. : Who ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), a Raleigh-based specialty pharmaceutical company focusing on innovative treatments for various gastrointestinal disorders, has been the top potential takeover target for some of the major pharmaceutical ...
Salix Pharmaceuticals Announces 4Q and FY2014 Financial Results ...  Investor's Business Daily
Salix Pharmaceuticals, Ltd Downgraded At UBS
UBS downgrades Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) stock from a Buy to a Hold rating, but increases its price target from $144 to $158.
Salix Pharmaceuticals (SLXP) Stock Price Target Increased Today at Cantor ...  TheStreet.com
SALIX PHARMACEUTICALS, LTD. SHAREHOLDER ALERT: Rigrodsky & Long ...  MarketWatch
Salix Pharmaceuticals, Ltd. (SLXP) Attracts Endo International's (ENDP) Attention
... is in the race to acquire Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), anonymous sources told Reuters. Endo, which focuses on pain management drugs, sent several letters to Salix, maker of drugs for bowel diseases, only to be rebuffed on many accounts.
Valeant Said to Secure Salix Financing, Closing In on Offer  Bloomberg
Bullish Salix Analyst Says Shares are Fairly Valued Absent a Deal  Wall Street Journal (blog)
Salix Pharmaceuticals, Ltd. Stockholders Encouraged to Contact Securities Law ...
27, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating the board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) in connection with a buyout for only $158.00 per share. Concerned SLXP investors are encouraged to contact ...
Salix Pharmaceuticals Ltd. (SLXP) Jumped On Reports Of Valeant Interest
Salix Pharmaceuticals rose sharply during the first 45 minutes of trade Friday, before settling into a range. Shares finished up by 7.11 at $157.85 on above average volume.
Canada's Valeant to buy Salix in $10.1 billion deal  Reuters
Canadian drug maker Valeant buying Salix Pharmaceuticals for $10B  CBC.ca
Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of Salix ...
WASHINGTON, Feb 24, 2015 (BUSINESS WIRE) -- The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Salix Pharmaceuticals, Ltd. (nasdaq gs:SLXP), concerning the Company's proposed acquisition by ...
Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States.
Stock Insight: Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)  Street Report
Average Price Target and Rating Consensus: Packaging Corp Of America , Salix ...  Wall Street Pulse
Ryan & Maniskas, LLP Announces Investigation of Salix Pharmaceuticals Ltd.
WAYNE, Pa., Feb. 24, 2015 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Salix Pharmaceuticals Ltd. ("Salix" or the "Company") (NASDAQ: SLXP) concerning possible breaches of fiduciary duty and ...